{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "datasets : INFO     : PyTorch version 2.6.0 available.\n"
     ]
    }
   ],
   "source": [
    "# Initialize your Co-STORM system\n",
    "from knowledge_storm.collaborative_storm.engine import CoStormRunner, RunnerArgument, CollaborativeStormLMConfigs, LoggingWrapper\n",
    "from knowledge_storm.encoder import Encoder\n",
    "from dotenv import load_dotenv\n",
    "\n",
    "load_dotenv()\n",
    "\n",
    "# Setup your runner\n",
    "lm_config = CollaborativeStormLMConfigs()\n",
    "args = RunnerArgument(topic=\"Cancer immunotherapy advances\")\n",
    "lm_config.init(lm_type=\"openai\")  # or \"azure\"\n",
    "encoder = Encoder()\n",
    "\n",
    "# Create the runner\n",
    "runner = CoStormRunner(\n",
    "    args=args,\n",
    "    lm_config=lm_config,\n",
    "    encoder=encoder,\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "# Initialize with some knowledge (optional)\n",
    "runner.warm_start()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "runner.conversation_history[7].to_dict()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "import json\n",
    "# save runner to json\n",
    "# runner_json = runner.to_dict()\n",
    "# with open(\"runner.json\", \"w\") as f:\n",
    "#     json.dump(runner_json, f)\n",
    "\n",
    "# load runner from json\n",
    "with open(\"runner.json\", \"r\") as f:\n",
    "    runner_json = json.load(f)\n",
    "runner = CoStormRunner.from_dict(runner_json)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\u001b[92m12:47:27 - LiteLLM:INFO\u001b[0m: utils.py:2974 - \n",
      "LiteLLM completion() model= gpt-4o-2024-05-13; provider = openai\n",
      "LiteLLM : INFO     : \n",
      "LiteLLM completion() model= gpt-4o-2024-05-13; provider = openai\n",
      "\u001b[92m12:47:32 - LiteLLM:INFO\u001b[0m: utils.py:1143 - Wrapper: Completed Call, calling success_handler\n",
      "LiteLLM : INFO     : Wrapper: Completed Call, calling success_handler\n",
      "\u001b[92m12:47:32 - LiteLLM:INFO\u001b[0m: utils.py:2974 - \n",
      "LiteLLM completion() model= gpt-4o-2024-05-13; provider = openai\n",
      "LiteLLM : INFO     : \n",
      "LiteLLM completion() model= gpt-4o-2024-05-13; provider = openai\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "RESEARCH IDEA:\n",
      "### Research Idea: Integrating Microbiome Modulation with CRISPR-Cas9 Enhanced T-cell Therapies for Improved Cancer Immunotherapy\n",
      "\n",
      "#### Description:\n",
      "Investigate the synergistic effects of microbiome modulation and CRISPR-Cas9 enhanced T-cell therapies on cancer treatment outcomes. This research would involve:\n",
      "1. Analyzing how specific microbiome compositions influence the efficacy of CRISPR-Cas9 edited T-cells in targeting cancer cells.\n",
      "2. Developing probiotic or prebiotic interventions to modulate the microbiome to an optimal state that enhances T-cell function and cancer cell recognition.\n",
      "3. Conducting preclinical trials to test the combination of microbiome modulation and CRISPR-Cas9 T-cell therapies in various cancer models, particularly those with challenging mutations like KRAS.\n",
      "\n",
      "#### Why It's Novel or Innovative:\n",
      "While both microbiome modulation and CRISPR-Cas9 enhanced T-cell therapies are individually explored, their combination represents a novel approach. Leveraging the microbiome to potentially boost the efficacy and precision of genetically edited T-cells could lead to a breakthrough in cancer treatment, offering a highly personalized and potent therapeutic strategy.\n",
      "\n",
      "#### How It Relates to the Current Discussion:\n",
      "This idea integrates the current advancements in CRISPR-Cas9 technology and the emerging interest in the microbiome's role in cancer therapy response. It builds upon the known challenges and limitations of current immunotherapies by proposing a dual approach that could overcome existing barriers and improve patient outcomes.\n",
      "\n",
      "--------------------------------------------------------------------------------\n",
      "\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\u001b[92m12:47:36 - LiteLLM:INFO\u001b[0m: utils.py:1143 - Wrapper: Completed Call, calling success_handler\n",
      "LiteLLM : INFO     : Wrapper: Completed Call, calling success_handler\n",
      "\u001b[92m12:47:36 - LiteLLM:INFO\u001b[0m: utils.py:2974 - \n",
      "LiteLLM completion() model= gpt-4o-2024-05-13; provider = openai\n",
      "LiteLLM : INFO     : \n",
      "LiteLLM completion() model= gpt-4o-2024-05-13; provider = openai\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "ASSESSMENT:\n",
      "### Assessment:\n",
      "\n",
      "#### Novelty: 9/10\n",
      "Combining microbiome modulation with CRISPR-Cas9 enhanced T-cell therapies is a highly original idea. Both fields are cutting-edge individually, and their intersection could yield unprecedented insights and therapeutic strategies. This level of integration has not been widely explored, making it a novel proposition.\n",
      "\n",
      "#### Feasibility: 6/10\n",
      "The practicality of this idea faces several challenges. Microbiome modulation and CRISPR-Cas9 T-cell therapies are complex on their own, and combining them adds layers of complexity. The development of effective probiotic or prebiotic interventions tailored to enhance CRISPR-edited T-cells would require extensive research and robust preclinical models. However, recent advancements in both fields suggest that with adequate funding and collaboration, these hurdles could be overcome.\n",
      "\n",
      "#### Value: 8/10\n",
      "If successful, this research could revolutionize cancer immunotherapy. By enhancing the efficacy and precision of T-cell therapies through microbiome modulation, this approach could lead to more personalized and effective treatments, particularly for cancers with challenging mutations. The potential to improve patient outcomes significantly justifies the high value.\n",
      "\n",
      "#### Relevance: 9/10\n",
      "This idea is highly relevant to the topic of cancer immunotherapy advances. It addresses current limitations and leverages emerging trends in microbiome research and gene editing technologies. The proposed dual approach aligns well with ongoing discussions and efforts to enhance cancer treatment efficacy and personalization.\n",
      "\n",
      "### Summary:\n",
      "This research idea is both innovative and timely, aligning closely with current advancements in cancer immunotherapy. While it presents significant challenges in terms of feasibility, the potential benefits and high relevance to the field make it a compelling area for further investigation.\n",
      "\n",
      "--------------------------------------------------------------------------------\n",
      "\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\u001b[92m12:47:46 - LiteLLM:INFO\u001b[0m: utils.py:1143 - Wrapper: Completed Call, calling success_handler\n",
      "LiteLLM : INFO     : Wrapper: Completed Call, calling success_handler\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "EXPERIMENTAL PLAN:\n",
      "### Experimental Plan for Integrating Microbiome Modulation with CRISPR-Cas9 Enhanced T-cell Therapies for Improved Cancer Immunotherapy\n",
      "\n",
      "#### 1. Methodology\n",
      "**Phase 1: Preliminary Research and Model Establishment**\n",
      "- **Literature Review**: Conduct a thorough review of existing studies on microbiome influence on T-cell function and CRISPR-Cas9 T-cell therapies.\n",
      "- **Microbiome Profiling**: Identify microbiome compositions that have shown to positively influence immune responses in cancer patients.\n",
      "- **CRISPR-Cas9 T-cell Design**: Develop CRISPR-Cas9 edited T-cells targeting specific cancer antigens, focusing initially on cancers with challenging mutations like KRAS.\n",
      "- **In Vitro Studies**: Assess the influence of various microbiome compositions on the efficacy of CRISPR-Cas9 edited T-cells in controlled environments.\n",
      "\n",
      "**Phase 2: Development of Probiotic/Prebiotic Interventions**\n",
      "- **Microbiome Modulation**: Develop probiotic or prebiotic formulations aimed at achieving the optimal microbiome state identified in Phase 1.\n",
      "- **Toxicology and Safety Testing**: Conduct initial safety assessments of the probiotic/prebiotic formulations in animal models.\n",
      "\n",
      "**Phase 3: Preclinical Trials**\n",
      "- **Animal Models**: Use mice models with induced cancers (including KRAS mutations) to test the combination of microbiome modulation and CRISPR-Cas9 T-cell therapies.\n",
      "- **Treatment Protocols**: Administer the probiotic/prebiotic interventions followed by CRISPR-Cas9 T-cell therapy and monitor tumor growth and immune response.\n",
      "- **Data Collection**: Evaluate tumor regression, T-cell activity, cytokine production, and overall survival rates.\n",
      "\n",
      "#### 2. Required Resources\n",
      "- **Tools and Equipment**: CRISPR-Cas9 gene editing tools, sequencing equipment for microbiome analysis, bioreactors for probiotic/prebiotic production, animal housing and monitoring systems.\n",
      "- **Data**: Access to cancer genomic databases, microbiome datasets, and immunotherapy outcome records.\n",
      "- **Expertise**: Collaborative team with expertise in oncology, microbiology, immunology, CRISPR technology, bioinformatics, and pharmacology.\n",
      "\n",
      "#### 3. Potential Challenges\n",
      "- **Complex Interactions**: The interaction between microbiome and immune cells is complex and may vary between individuals, requiring extensive personalization.\n",
      "- **Regulatory Hurdles**: Ensuring regulatory compliance for novel microbiome-modulating interventions and genetically edited T-cells.\n",
      "- **Ethical Considerations**: Ethical approval for animal studies and future human clinical trials.\n",
      "- **Technical Difficulties**: Ensuring the stability and viability of CRISPR-edited T-cells and probiotics in vivo.\n",
      "\n",
      "**Mitigation Strategies**\n",
      "- **Personalization Algorithms**: Develop computational models to predict optimal microbiome states for individual patients.\n",
      "- **Stepwise Regulatory Engagement**: Early and continuous engagement with regulatory bodies to ensure compliance.\n",
      "- **Ethics Board Involvement**: Regular consultations with ethics boards to address any concerns promptly.\n",
      "- **Optimization Protocols**: Establish robust protocols for the production and preservation of therapeutic agents.\n",
      "\n",
      "#### 4. Timeline\n",
      "- **Phase 1**: 6-12 months\n",
      "- **Phase 2**: 12-18 months\n",
      "- **Phase 3**: 18-24 months\n",
      "- **Total Duration**: Approximately 3.5 to 4 years\n",
      "\n",
      "#### 5. Expected Outcomes\n",
      "- **Validation Outcomes**: Identification of specific microbiome compositions that significantly enhance the efficacy of CRISPR-Cas9 edited T-cells.\n",
      "- **Clinical Insights**: Data on the safety and effectiveness of probiotic/prebiotic interventions combined with CRISPR-Cas9 T-cell therapies.\n",
      "- **Therapeutic Protocols**: Development of preliminary therapeutic protocols for combined microbiome modulation and gene-edited T-cell therapies.\n",
      "- **Future Research Directions**: Identification of new research avenues based on findings, potentially leading to human clinical trials.\n",
      "\n",
      "This plan provides a comprehensive framework for exploring the synergistic potential of microbiome modulation and CRISPR-Cas9 enhanced T-cell therapies in cancer immunotherapy.\n",
      "\n",
      "--------------------------------------------------------------------------------\n",
      "\n"
     ]
    }
   ],
   "source": [
    "\n",
    "# Now use the direct research capabilities:\n",
    "\n",
    "# 1. Generate a research idea\n",
    "idea = runner.generate_research_idea(\n",
    "    context=\"Consider the role of the microbiome in cancer therapy response\"\n",
    ")\n",
    "print(\"RESEARCH IDEA:\")\n",
    "print(idea)\n",
    "print(\"\\n\" + \"-\"*80 + \"\\n\")\n",
    "\n",
    "# 2. Assess the idea\n",
    "assessment = runner.assess_research_idea(idea)\n",
    "print(\"ASSESSMENT:\")\n",
    "print(assessment)\n",
    "print(\"\\n\" + \"-\"*80 + \"\\n\")\n",
    "\n",
    "# 3. Create an experimental plan\n",
    "plan = runner.create_experimental_plan(idea, assessment)\n",
    "print(\"EXPERIMENTAL PLAN:\")\n",
    "print(plan)\n",
    "print(\"\\n\" + \"-\"*80 + \"\\n\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "5"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "runner.add_researcher(role_name=\"Research Scientist\", role_description=\"Specializes in generating novel research ideas and experimental plans\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\u001b[92m12:49:32 - LiteLLM:INFO\u001b[0m: utils.py:2974 - \n",
      "LiteLLM completion() model= gpt-4o-2024-05-13; provider = openai\n",
      "LiteLLM : INFO     : \n",
      "LiteLLM completion() model= gpt-4o-2024-05-13; provider = openai\n",
      "\u001b[92m12:49:33 - LiteLLM:INFO\u001b[0m: utils.py:1143 - Wrapper: Completed Call, calling success_handler\n",
      "LiteLLM : INFO     : Wrapper: Completed Call, calling success_handler\n",
      "\u001b[92m12:49:33 - LiteLLM:INFO\u001b[0m: utils.py:2974 - \n",
      "LiteLLM completion() model= gpt-4o-2024-05-13; provider = openai\n",
      "LiteLLM : INFO     : \n",
      "LiteLLM completion() model= gpt-4o-2024-05-13; provider = openai\n",
      "\u001b[92m12:49:35 - LiteLLM:INFO\u001b[0m: utils.py:1143 - Wrapper: Completed Call, calling success_handler\n",
      "LiteLLM : INFO     : Wrapper: Completed Call, calling success_handler\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Error while requesting URL('https://ashpublications.org/blood/article/144/Supplement%201/4829/533290/CTX112-a-Next-Generation-Allogeneic-CRISPR-Cas9') - HTTPStatusError(\"Client error '403 Forbidden' for url 'https://ashpublications.org/blood/article/144/Supplement%201/4829/533290/CTX112-a-Next-Generation-Allogeneic-CRISPR-Cas9'\\nFor more information check: https://developer.mozilla.org/en-US/docs/Web/HTTP/Status/403\")\n",
      "Error while requesting URL('https://www.cell.com/cell/fulltext/S0092-8674(23)00975-3') - HTTPStatusError(\"Client error '403 Forbidden' for url 'https://www.cell.com/cell/fulltext/S0092-8674(23)00975-3'\\nFor more information check: https://developer.mozilla.org/en-US/docs/Web/HTTP/Status/403\")\n",
      "Error while requesting URL('https://www.sciencedirect.com/science/article/pii/S1465324924000604') - HTTPStatusError(\"Client error '403 Forbidden' for url 'https://www.sciencedirect.com/science/article/pii/S1465324924000604'\\nFor more information check: https://developer.mozilla.org/en-US/docs/Web/HTTP/Status/403\")\n",
      "Error while requesting URL('https://pmc.ncbi.nlm.nih.gov/articles/PMC11486967/') - HTTPStatusError(\"Client error '403 Forbidden' for url 'https://pmc.ncbi.nlm.nih.gov/articles/PMC11486967/'\\nFor more information check: https://developer.mozilla.org/en-US/docs/Web/HTTP/Status/403\")\n",
      "Error while requesting URL('https://pmc.ncbi.nlm.nih.gov/articles/PMC10666174/') - HTTPStatusError(\"Client error '403 Forbidden' for url 'https://pmc.ncbi.nlm.nih.gov/articles/PMC10666174/'\\nFor more information check: https://developer.mozilla.org/en-US/docs/Web/HTTP/Status/403\")\n",
      "Error while requesting URL('https://pmc.ncbi.nlm.nih.gov/articles/PMC7463827/') - HTTPStatusError(\"Client error '403 Forbidden' for url 'https://pmc.ncbi.nlm.nih.gov/articles/PMC7463827/'\\nFor more information check: https://developer.mozilla.org/en-US/docs/Web/HTTP/Status/403\")\n",
      "Error while requesting URL('https://pmc.ncbi.nlm.nih.gov/articles/PMC10613999/') - HTTPStatusError(\"Client error '403 Forbidden' for url 'https://pmc.ncbi.nlm.nih.gov/articles/PMC10613999/'\\nFor more information check: https://developer.mozilla.org/en-US/docs/Web/HTTP/Status/403\")\n",
      "Error while requesting URL('https://www.sciencedirect.com/science/article/pii/S2772906024000979') - HTTPStatusError(\"Client error '403 Forbidden' for url 'https://www.sciencedirect.com/science/article/pii/S2772906024000979'\\nFor more information check: https://developer.mozilla.org/en-US/docs/Web/HTTP/Status/403\")\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\u001b[92m12:49:38 - LiteLLM:INFO\u001b[0m: utils.py:2974 - \n",
      "LiteLLM completion() model= gpt-4o-2024-05-13; provider = openai\n",
      "LiteLLM : INFO     : \n",
      "LiteLLM completion() model= gpt-4o-2024-05-13; provider = openai\n",
      "\u001b[92m12:49:42 - LiteLLM:INFO\u001b[0m: utils.py:1143 - Wrapper: Completed Call, calling success_handler\n",
      "LiteLLM : INFO     : Wrapper: Completed Call, calling success_handler\n",
      "\u001b[92m12:49:42 - LiteLLM:INFO\u001b[0m: utils.py:2974 - \n",
      "LiteLLM completion() model= gpt-4o-2024-05-13; provider = openai\n",
      "LiteLLM : INFO     : \n",
      "LiteLLM completion() model= gpt-4o-2024-05-13; provider = openai\n",
      "\u001b[92m12:49:46 - LiteLLM:INFO\u001b[0m: utils.py:1143 - Wrapper: Completed Call, calling success_handler\n",
      "LiteLLM : INFO     : Wrapper: Completed Call, calling success_handler\n",
      "\u001b[92m12:49:46 - LiteLLM:INFO\u001b[0m: utils.py:1143 - Wrapper: Completed Call, calling success_handler\n",
      "LiteLLM : INFO     : Wrapper: Completed Call, calling success_handler\n",
      "\u001b[92m12:49:46 - LiteLLM:INFO\u001b[0m: utils.py:2974 - \n",
      "LiteLLM completion() model= gpt-4o-2024-05-13; provider = openai\n",
      "LiteLLM : INFO     : \n",
      "LiteLLM completion() model= gpt-4o-2024-05-13; provider = openai\n",
      "\u001b[92m12:49:47 - LiteLLM:INFO\u001b[0m: utils.py:1143 - Wrapper: Completed Call, calling success_handler\n",
      "LiteLLM : INFO     : Wrapper: Completed Call, calling success_handler\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "<knowledge_storm.dataclass.ConversationTurn at 0x13b835f90>"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "runner.step()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\u001b[92m12:49:59 - LiteLLM:INFO\u001b[0m: utils.py:2974 - \n",
      "LiteLLM completion() model= gpt-4o-2024-05-13; provider = openai\n",
      "LiteLLM : INFO     : \n",
      "LiteLLM completion() model= gpt-4o-2024-05-13; provider = openai\n",
      "\u001b[92m12:49:59 - LiteLLM:INFO\u001b[0m: utils.py:2974 - \n",
      "LiteLLM completion() model= gpt-4o-2024-05-13; provider = openai\n",
      "LiteLLM : INFO     : \n",
      "LiteLLM completion() model= gpt-4o-2024-05-13; provider = openai\n",
      "\u001b[92m12:49:59 - LiteLLM:INFO\u001b[0m: utils.py:2974 - \n",
      "LiteLLM completion() model= gpt-4o-2024-05-13; provider = openai\n",
      "LiteLLM : INFO     : \n",
      "LiteLLM completion() model= gpt-4o-2024-05-13; provider = openai\n",
      "\u001b[92m12:49:59 - LiteLLM:INFO\u001b[0m: utils.py:2974 - \n",
      "LiteLLM completion() model= gpt-4o-2024-05-13; provider = openai\n",
      "LiteLLM : INFO     : \n",
      "LiteLLM completion() model= gpt-4o-2024-05-13; provider = openai\n",
      "\u001b[92m12:50:04 - LiteLLM:INFO\u001b[0m: utils.py:1143 - Wrapper: Completed Call, calling success_handler\n",
      "LiteLLM : INFO     : Wrapper: Completed Call, calling success_handler\n",
      "\u001b[92m12:50:04 - LiteLLM:INFO\u001b[0m: utils.py:1143 - Wrapper: Completed Call, calling success_handler\n",
      "LiteLLM : INFO     : Wrapper: Completed Call, calling success_handler\n",
      "\u001b[92m12:50:05 - LiteLLM:INFO\u001b[0m: utils.py:1143 - Wrapper: Completed Call, calling success_handler\n",
      "LiteLLM : INFO     : Wrapper: Completed Call, calling success_handler\n",
      "\u001b[92m12:50:06 - LiteLLM:INFO\u001b[0m: utils.py:1143 - Wrapper: Completed Call, calling success_handler\n",
      "LiteLLM : INFO     : Wrapper: Completed Call, calling success_handler\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "'# Introduction to Recent Advances in Cancer Immunotherapy\\nCancer immunotherapy has significantly evolved as a prominent modality for treating various cancers, leveraging the body\\'s immune system to identify and destroy cancer cells. Recent advances in this field have introduced multiple innovative treatment approaches, including therapeutic vaccines, immune checkpoint blockade, bispecific T-cell engagers (BiTEs), and adoptive cell therapies, all of which primarily aim to elicit a T-cell-based immune response against tumor antigens[1]. These therapies are not only focused on enhancing the adaptive immune response but also involve interactions with the innate immune system, particularly antigen-presenting cells, which play a crucial role in the overall efficacy of these treatments.\\n\\nOne notable advancement in 2023 is the integration of CRISPR-Cas9 technology into cancer immunotherapy. This cutting-edge genome-editing tool has been utilized to enhance the precision and effectiveness of immune responses against cancer, offering new avenues for treatment development and application[2]. Additionally, the combination of immunotherapy with targeted inhibitors has shown promising results. For instance, adding immunotherapy to inhibitors targeting multiple forms of the KRAS gene mutation has significantly prolonged the control of pancreatic cancer in preclinical models, suggesting potential benefits for future clinical trials[3].\\n\\nIn a remarkable clinical trial conducted in April 2023, researchers at Mass General in Boston treated a patient with glioblastoma by infusing genetically modified white blood cells directly into the brain\\'s surrounding fluid. This innovative approach demonstrated the potential for rapid and effective treatment responses, albeit with some initial concerns about patient safety[4]. These examples illustrate the rapid advancements and ongoing innovations in cancer immunotherapy, highlighting the potential for new and more effective treatments in the fight against cancer.\\n# Targeting KRAS Mutations in Cancer Treatment\\n\\n## Challenges of KRAS Mutations\\nKRAS mutations represent one of the most challenging targets in cancer treatment, particularly in non-small cell lung cancer (NSCLC). These mutations occur in approximately 30% of NSCLCs, making KRAS the most frequently mutated gene in this type of cancer[8]. The difficulties in targeting KRAS mutations stem from several factors, starting with the nature of the KRAS protein itself. Mutant KRAS proteins often remain in an active \"on\" state, continuously driving cell growth and proliferation through multiple signaling pathways[8][9].\\n\\nOne of the significant obstacles is the biochemical properties of the KRAS protein, which make it a notoriously difficult target for drug development. Traditional small molecule inhibitors often fail to effectively bind to the KRAS protein due to its high affinity for GTP/GDP and lack of suitable binding pockets[9][10]. As a result, KRAS was long considered \"undruggable\"[10].\\n\\nDespite these challenges, recent breakthroughs have shown promise in targeting KRAS mutations. The advent of KRAS G12C inhibitors, such as sotorasib and adagrasib, marks a significant advancement. These inhibitors target the specific KRAS G12C mutation, locking the protein in an inactive state and thereby blocking the downstream signaling that promotes cancer cell growth[6][10]. However, resistance to these inhibitors can develop, necessitating combination strategies to improve efficacy[5][11].\\n\\nAnother promising approach involves combining KRAS inhibitors with other therapies, including immunotherapies. Early clinical data suggest that pairing KRAS inhibitors with drugs targeting other pathways, like RAF/MEK or FAK inhibitors, could enhance treatment outcomes[11]. Additionally, combining these targeted therapies with immunotherapies holds potential, as it could help to overcome resistance mechanisms and sustain long-term responses[5][7].\\n## New Inhibitors Overcoming \"Undruggable\" Targets\\nRecent advancements in cancer immunotherapy have introduced new inhibitors designed to target previously \"undruggable\" mutations, specifically in the KRAS gene. The KRAS mutation is implicated in some of the most lethal forms of cancer, such as pancreatic and non-small cell lung cancer (NSCLC), presenting a significant challenge due to its historically resistant nature to targeted therapies.\\n\\nA breakthrough by researchers at The University of Texas MD Anderson Cancer Center has shown promise in preclinical models of pancreatic cancer with the KRAS G12D mutation. The novel therapeutic approach combines a KRAS G12D inhibitor with immune checkpoint inhibitors, resulting in durable tumor elimination and significantly improved survival outcomes. This preclinical success has led to the initiation of a Phase I clinical trial, suggesting a potential new avenue for treating KRAS-mutant cancers[22].\\n\\nFurther research from the Perelman School of Medicine at the University of Pennsylvania and Penn Medicine’s Abramson Cancer Center supports these findings. Their studies revealed that combining immunotherapy with inhibitors targeting multiple forms of KRAS mutations significantly extended the period during which pancreatic cancer was kept at bay compared to using the targeted therapy alone. This combination therapy is now being primed for future clinical trials[24].\\n\\nMoreover, the development of these inhibitors has shown an additional mechanism by which they enhance the effectiveness of immunotherapies. Research teams have discovered that the process by which cells degrade proteins into peptides allows fragments of the KRAS-targeted drug-bound mutant protein to present on the cell surface. This presentation can flag the cell for destruction by the immune system, effectively allowing KRAS-targeted drugs to perform dual roles as targeted therapy and immunotherapy[23].\\n\\nThe application of immune checkpoint inhibitors, such as PD-1/L1 inhibitors, has also been studied in KRAS-mutant NSCLC. A multicenter retrospective real-world study published in BMC Cancer evaluated the effectiveness of these inhibitors as first-line immunotherapy for advanced NSCLC patients harboring KRAS mutations. The study\\'s results add to the growing body of evidence supporting the potential of combining targeted inhibitors with immunotherapies to improve outcomes for patients with KRAS-mutant cancers[25].\\n\\nThese advancements signify a pivotal shift in the treatment landscape for cancers driven by KRAS mutations, highlighting the potential of new inhibitors to overcome previously \"undruggable\" targets and enhance the efficacy of immunotherapies.\\n## Clinical Trials on KRAS Mutation Therapies\\n### Clinical Trials on KRAS Mutation Therapies\\n\\nKRAS mutations are highly prevalent in non-small cell lung cancer (NSCLC) and are typically associated with poor outcomes in immunotherapy treatments. This has led to significant research aimed at understanding how these mutations, including their subtypes and associated co-mutations, influence the efficacy of immunotherapy. A recent systematic review and meta-analysis published in \"Cancer Cell International\" sought to assess the impact of KRAS mutations on the effectiveness of immunotherapy in NSCLC[26].\\n\\nThe study highlights that while the presence of KRAS mutations often correlates with a lower response rate to immunotherapies, novel therapeutic approaches and inhibitors are being developed to address this challenge. These new inhibitors are designed to specifically target KRAS mutations, potentially enhancing the efficacy of immunotherapies. Clinical trials have been pivotal in evaluating the effectiveness and safety of these new treatments. Results from these trials suggest that while the new inhibitors show promise, their impact can vary based on the specific subtype of the KRAS mutation and the presence of other co-mutations[26].\\n# Advancements in Immune Checkpoint Inhibitors\\n### Advancements in Immune Checkpoint Inhibitors\\n\\nImmune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, offering durable clinical benefits and potential cures for some patients. Recent advancements in this field are improving patient outcomes by targeting specific proteins and refining treatment strategies.\\n\\n#### Novel Targets and Combination Therapies\\n\\nThe approval of ICIs targeting proteins such as CTLA-4, PD-1, and PD-L1 has already been a significant milestone in cancer treatment. More recently, the FDA\\'s endorsement of inhibitors targeting LAG-3 (Lymphocyte Activation Gene 3) has opened new therapeutic possibilities[15]. These novel targets are being explored to enhance the efficacy of existing treatments and address resistance mechanisms[12][13].\\n\\n#### Personalized Immunotherapy\\n\\nRecent advances emphasize the personalization of cancer immunotherapy. Tailoring treatments to the individual patient\\'s tumor biology and immune environment helps optimize the response to ICIs[16]. The integration of T cells and cancer vaccines with ICIs is being investigated to boost the anti-tumor immune response further, offering a more comprehensive approach to treatment[16].\\n\\n#### Sensitizing Tumors to ICIs\\n\\nOngoing research is focused on sensitizing tumors to ICIs. This includes understanding the underlying biology of anti-tumor immunity and identifying predictive biomarkers to select patients who are most likely to benefit from these therapies[12][14]. These efforts aim to maximize efficacy while minimizing toxicities.\\n\\n#### Clinical Trials and Regional Analysis\\n\\nComprehensive analyses of clinical trials, such as those conducted by Novotech, reveal key findings and regional trends in the use of ICIs. These insights help in refining therapeutic strategies and understanding the global landscape of immunotherapy advancements[15].\\n\\n#### Future Directions\\n\\nFuture strategies involve combinatorial approaches with traditional treatments like chemotherapy and radiation to enhance the overall therapeutic effect[15]. Additionally, addressing current challenges such as immune and non-immune factors regulating the response to ICIs remains a priority[12]. Ongoing efforts aim to guide the development of subsequent clinical trials and improve patient outcomes through innovative treatments[12][17].\\n# Precision Enhancement in T-cell Therapies Using CRISPR-Cas9\\nThe precision of T-cell-based therapies in cancer immunotherapy has been significantly enhanced through the application of CRISPR/Cas9 technology. CRISPR/Cas9, a robust and versatile genome-editing tool, allows for precise modifications in the genome, thereby increasing the efficacy and safety of T-cell therapies[18][19]. This technology is used to knockout, knock-in, or perform genome-wide screens in T cells, optimizing their ability to target and destroy cancer cells[20].\\n\\nCRISPR/Cas9 has revitalized adoptive T-cell therapy by enabling more accurate genetic alterations. Researchers are utilizing this system to edit T cells in a way that enhances their ability to recognize and attack cancer cells without harming healthy tissues[21]. The development of high-specificity guide RNA (gRNA) databases, such as GuideScan2, has further minimized off-target effects, which is crucial for ensuring the safety and effectiveness of these therapies[39][40][41]. Innovations in gRNA design, taking into account RNA structure and sequence composition, have led to improved targeting precision and reduced off-target effects, thereby optimizing the outcomes of CRISPR-based genome editing[41].\\n\\nHigh-fidelity variants of the Cas9 enzyme, like spCas9 from Streptococcus pyogenes, have also been developed to enhance DNA targeting accuracy, addressing concerns about off-target activity and making CRISPR applications safer for therapeutic use[42]. These advances are not just theoretical; they are being actively applied in clinical trials to improve cancer treatments. For instance, the latest clinical trials at Memorial Sloan Kettering Cancer Center (MSK) involve CAR T cells engineered with CRISPR/Cas9 to make the therapy even more precise and potent against blood cancers like leukemia and lymphoma[44].\\n# Bispecific T-cell Engagers (BiTEs) in Cancer Immunotherapy\\n### Bispecific T-cell Engagers (BiTEs) in Cancer Immunotherapy\\n\\nBispecific T-cell engagers (BiTEs) represent a significant advancement in the field of cancer immunotherapy. BiTEs are artificial bispecific monoclonal antibodies designed to enhance the body\\'s immune response against cancer cells. These molecules act by forming a direct link between T cells, a critical component of the immune system, and tumor cells. This bridging facilitates the T cells\\' ability to recognize and destroy cancer cells[1][2].\\n\\nBiTE molecules are fusion proteins made up of two single-chain variable fragments (scFvs) derived from different antibodies, or amino acid sequences from four distinct genes, assembled on a single peptide chain of approximately 55 kilodaltons. One of the scFvs targets T cells by binding to the CD3 receptor, while the other binds to a tumor-specific molecule on the cancer cell[1]. This dual-binding mechanism enables BiTEs to bring T cells into close proximity with tumor cells, thereby promoting the T cells\\' cytotoxic activity against the cancerous cells.\\n\\nSeveral BiTE therapies have been approved for the treatment of specific forms of blood cancer. By linking T cells and tumor cells, these therapies enhance the immune system\\'s capacity to target and eliminate cancer cells more effectively[3]. However, it is important to note that BiTE therapies can have serious side effects, necessitating close medical supervision, especially during the initial doses[3].\\n\\nThe ongoing development and refinement of BiTEs have opened new avenues for targeting malignancies that were previously difficult to treat with conventional therapies. Innovations in their molecular design, immune interactions, and production techniques continue to drive their therapeutic applications forward, providing hope for more effective cancer treatments in the future[4][5].\\n# Challenges and Limitations in CRISPR-Cas9 Applications\\nCRISPR-Cas9 technology holds significant promise for advancing cancer immunotherapy; however, its clinical application comes with notable challenges and limitations. One of the primary concerns is the risk of off-target effects, where the CRISPR-Cas9 system might introduce unintended genetic modifications that could lead to adverse outcomes, including tumorigenesis or disruption of vital gene functions[38]. This potential for off-target DNA cleavage necessitates the development of more precise genome-editing tools and rigorous validation protocols to ensure safety in clinical settings[38].\\n\\nAnother major challenge is the efficient delivery of the CRISPR-Cas9 components to the target cells within the human body[32]. Effective delivery mechanisms are crucial for ensuring that the gene-editing system reaches the appropriate cells without eliciting an immune response or being degraded before it can perform its function. Researchers are exploring various vectors, including viral and non-viral systems, to improve delivery efficiency and specificity[33][34].\\n\\nAdditionally, the heterogeneity of tumors poses a significant obstacle. Cancer cells within the same tumor can exhibit genetic diversity, making it challenging to design CRISPR-Cas9 interventions that effectively target all cancerous cells without affecting normal cells[35]. This necessitates a personalized approach to CRISPR-Cas9 therapy, where treatments are tailored to the unique genetic profile of an individual’s tumor.\\n\\nThere are also concerns regarding the ethical implications and long-term effects of genome editing. The potential for heritable changes means that modifications made to the genome could be passed on to future generations, raising ethical questions about consent and the long-term impact on human genetics[36].\\n\\nTo address these challenges, researchers are developing more accurate CRISPR systems with reduced off-target effects, improving delivery methods, and conducting extensive preclinical and clinical studies to better understand the long-term implications of genome editing[37]. These efforts are essential for translating the promise of CRISPR-Cas9 technology into safe and effective cancer immunotherapies.'"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "runner.generate_report()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "# 4. Or run the complete research pipeline at once\n",
    "research_output = runner.research_pipeline(\n",
    "    context=\"Novel applications of mRNA technology beyond vaccines\"\n",
    ")\n",
    "print(\"COMPLETE RESEARCH OUTPUT:\")\n",
    "print(f\"Idea: {research_output['idea'][:100]}...\")\n",
    "print(f\"Assessment: {research_output['assessment'][:100]}...\")\n",
    "print(f\"Plan: {research_output['plan'][:100]}...\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "# 1. Generate a research idea\n",
    "idea = runner.generate_research_idea(\n",
    "    context=\"Consider the role of the microbiome in cancer therapy response\"\n",
    ")\n",
    "print(\"RESEARCH IDEA:\")\n",
    "print(idea)\n",
    "print(\"\\n\" + \"-\"*80 + \"\\n\")\n",
    "\n",
    "# 2. Assess the idea\n",
    "assessment = runner.assess_research_idea(idea)\n",
    "print(\"ASSESSMENT:\")\n",
    "print(assessment)\n",
    "print(\"\\n\" + \"-\"*80 + \"\\n\")\n",
    "\n",
    "# 3. Create an experimental plan\n",
    "plan = runner.create_experimental_plan(idea, assessment)\n",
    "print(\"EXPERIMENTAL PLAN:\")\n",
    "print(plan)\n",
    "print(\"\\n\" + \"-\"*80 + \"\\n\")\n",
    "\n",
    "# 4. Or run the complete research pipeline at once\n",
    "research_output = runner.research_pipeline(\n",
    "    context=\"Novel applications of mRNA technology beyond vaccines\"\n",
    ")\n",
    "print(\"COMPLETE RESEARCH OUTPUT:\")\n",
    "print(f\"Idea: {research_output['idea'][:100]}...\")\n",
    "print(f\"Assessment: {research_output['assessment'][:100]}...\")\n",
    "print(f\"Plan: {research_output['plan'][:100]}...\")"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": ".venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.13.2"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
